Free Trial Information
BioCentury | May 6, 2019
Distillery Therapeutics

PARG inhibition for ovarian cancer

...Inc. include developing undisclosed PARG inhibitors for an undisclosed indication. Eli Lilly and Co. and Esperas Pharma Inc....
Read More
BioCentury | May 2, 2016
Clinical News

ESP-01: Phase Ib/IIa started

...or ovarian cancer. Esperas has worldwide rights to develop and commercialize ESP-01 from Eli Lilly. Esperas Pharma Inc....
Read More
BioCentury | Apr 20, 2015
Financial News

Esperas Pharma completes venture financing

Esperas Pharma Inc. , Montreal, Quebec Business: Cancer Date completed: 2015-04-13 Type: Venture financing Raised: $16.5 million Investors: TVM Life Science Ventures; Fonds de solidarite FTQ WIR Staff cancer...
Read More
Items per page:
1 - 3 of 3
BioCentury | May 6, 2019
Distillery Therapeutics

PARG inhibition for ovarian cancer

...Inc. include developing undisclosed PARG inhibitors for an undisclosed indication. Eli Lilly and Co. and Esperas Pharma Inc....
Read More
BioCentury | May 2, 2016
Clinical News

ESP-01: Phase Ib/IIa started

...or ovarian cancer. Esperas has worldwide rights to develop and commercialize ESP-01 from Eli Lilly. Esperas Pharma Inc....
Read More
BioCentury | Apr 20, 2015
Financial News

Esperas Pharma completes venture financing

Esperas Pharma Inc. , Montreal, Quebec Business: Cancer Date completed: 2015-04-13 Type: Venture financing Raised: $16.5 million Investors: TVM Life Science Ventures; Fonds de solidarite FTQ WIR Staff cancer...
Read More
Items per page:
1 - 3 of 3